A post hoc analysis of the phase III AURIGA study showed that the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) for multiple myeloma in the post-transplant maintenance setting improved ...

BOSTON, May 20 (Reuters) - Two major studies of Celgene Corp's multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem cell transplantation it reduced the risk of ...

Ashraf Badros, MB, ChB, professor at the University of Maryland School of Medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in ...

Please provide your email address to receive an email when new articles are posted on . Patients had a reduced risk for disease progression or death when treated with daratumumab-lenalidomide vs.

RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual disease ...

The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malattie Ematologiche dell'Adulto ...

BOSTON, June 6 (Reuters) - Two major studies of Celgene Corp's multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem-cell transplantation it reduced the risk of ...

Lenalidomide maintenance therapy in patients with MM reduces antibody production but preserves T-cell responses post-vaccination. mRNA vaccines enhance CD4+ and CD8+ responses, providing protective ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

SAN DIEGO -- Patients with newly diagnosed multiple myeloma had almost a 60% improvement in progression-free survival (PFS) if they received the anti-CD38 daratumumab (Darzalex) in addition to ...